Artivion Gestione

Gestione criteri di controllo 4/4

Artivion Il CEO è Pat Mackin, nominato in Sep2014, e ha un mandato di 10.17 anni. la retribuzione annua totale è $ 3.18M, composta da 24.4% di stipendio e 75.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.59% delle azioni della società, per un valore di $ 18.67M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.3 anni e 8.1 anni.

Informazioni chiave

Pat Mackin

Amministratore delegato

US$3.2m

Compenso totale

Percentuale dello stipendio del CEO	24.4%
Mandato del CEO	10.2yrs
Proprietà del CEO	1.6%
Durata media del management	4.3yrs
Durata media del Consiglio di amministrazione	8.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Nov 23

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Oct 13

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Jul 20

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 10

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Mar 09

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Feb 16

Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold

Dec 18

Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Sep 29

Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver

Sep 27

Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M

Aug 04

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Pat Mackin rispetto agli utili di Artivion?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$842k
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$3m	US$776k	-US$31m
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	n/a	n/a	-US$28m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$7m	US$750k	-US$19m
Sep 30 2022	n/a	n/a	-US$41m
Jun 30 2022	n/a	n/a	-US$17m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$5m	US$728k	-US$15m
Sep 30 2021	n/a	n/a	US$2m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$13m
Dec 31 2020	US$3m	US$606k	-US$17m
Sep 30 2020	n/a	n/a	-US$14m
Jun 30 2020	n/a	n/a	-US$11m
Mar 31 2020	n/a	n/a	-US$5m
Dec 31 2019	US$6m	US$689k	US$2m
Sep 30 2019	n/a	n/a	US$2m
Jun 30 2019	n/a	n/a	US$3m
Mar 31 2019	n/a	n/a	US$709k
Dec 31 2018	US$3m	US$660k	-US$3m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$2m
Dec 31 2017	US$3m	US$640k	US$4m

Compensazione vs Mercato: La retribuzione totale di Pat ($USD 3.18M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 3.19M ).

Compensazione vs guadagni: La retribuzione di Pat è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Pat Mackin (57 yo)

10.2yrs

Mandato

US$3,176,413

Compensazione

Mr. James Patrick Mackin, also known as Pat, has been the Chief Executive Officer and President of Artivion, Inc. (formerly known as CryoLife, Inc.) since September 02, 2014 and has been its Chairman since...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
James Mackin	Chairman	10.2yrs	US$3.18m	1.59% $ 18.7m
Lance Berry	Executive VP of Finance	less than a year	US$1.64m	0.19% $ 2.2m
Amy Horton	VP & Chief Accounting Officer	18.3yrs	US$1.06m	0.33% $ 3.9m
Jean Holloway	Senior VP	9.6yrs	US$993.72k	0.39% $ 4.5m
John Davis	Senior VP & Chief Commercial Officer	less than a year	US$953.41k	0.38% $ 4.4m
Matthew Getz	VP of Human Resources & Chief Human Resources Officer	5.3yrs	Nessun dato	0.081% $ 956.2k
Marshall Stanton	Senior VP of Clinical Research & Chief Medical Officer	3.7yrs	US$1.61m	0.20% $ 2.3m
Robert Thomson	Vice President of Research & Development	1.4yrs	Nessun dato	0.032% $ 372.6k
Florian Tyrs	Vice President of Global Operations	4.3yrs	Nessun dato	0.061% $ 720.0k

4.3yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di AORT è considerato esperto (durata media dell'incarico 4.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
James Mackin	Chairman	10.1yrs	US$3.18m	1.59% $ 18.7m
James Bullock	Independent Director	8.1yrs	US$217.50k	0.15% $ 1.7m
Thomas Ackerman	Independent Director	20.9yrs	US$230.00k	0.34% $ 4.0m
Anthony Semedo	Independent Director	3.1yrs	US$217.50k	0.081% $ 957.5k
Daniel Bevevino	Independent Director	20.9yrs	US$235.00k	0.34% $ 4.0m
Jeffrey Burbank	Independent Presiding Director	7.2yrs	US$265.00k	0.11% $ 1.3m
Jon Salveson	Independent Director	12.5yrs	US$215.00k	0.29% $ 3.5m
Marna Borgstrom	Independent Director	6.4yrs	US$220.00k	0.10% $ 1.2m
Elizabeth Hoff	Independent Director	2.1yrs	US$210.00k	0.060% $ 702.5k

8.1yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AORT sono considerati esperti (durata media dell'incarico 8.1 anni).

Artivion Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

VP & Chief Accounting Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Independent Director recently sold US$243k worth of stock

Independent Director notifies of intention to sell stock

Artivion, Inc., Annual General Meeting, May 14, 2024

Recent updates

Price target increased by 7.8% to US$33.17

Artivion, Inc. Lowers Earnings Guidance for the Full Year 2024

Artivion, Inc. Lowers Earnings Guidance for the Full Year 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

When Should You Buy Artivion, Inc. (NYSE:AORT)?

Insufficient new directors

Artivion, Inc. to Report Q3, 2024 Results on Nov 07, 2024

VP & Chief Accounting Officer notifies of intention to sell stock

Returns At Artivion (NYSE:AORT) Are On The Way Up

Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Insider notifies of intention to sell stock

Independent Director recently sold US$243k worth of stock

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS exceeds analyst expectations

Artivion, Inc. Revises Earnings Guidance for the Year 2024

Artivion, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Price target increased by 9.2% to US$27.47

Price target increased by 9.2% to US$27.47

Is Artivion (NYSE:AORT) A Risky Investment?

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Artivion, Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Artivion, Inc. to Report Q1, 2024 Results on May 06, 2024

Artivion, Inc., Annual General Meeting, May 14, 2024

New minor risk - Shareholder dilution

Chairman recently sold US$262k worth of stock

Chairman recently sold US$242k worth of stock

Chairman notifies of intention to sell stock

Consensus EPS estimates fall by 880%

Price target increased by 11% to US$25.15

Artivion, Inc. Provides Earnings Guidance for the Year 2024

Artivion, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Artivion, Inc. announced that it expects to receive $350 million in funding

Is Artivion (NYSE:AORT) Using Too Much Debt?

Senior VP notifies of intention to sell stock

Artivion Stock: A First Assessment

VP & Chief Accounting Officer notifies of intention to sell stock

Artivion, Inc. Announces Chief Financial Officer Changes

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Artivion, Inc. Announces Completion of Enrollment in PERSEVERE Trial

Consensus EPS estimates fall by 29%

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion, Inc. Revises Earnings Guidance for the Year 2023

Artivion, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Artivion, Inc. Announces Data from On-X Aortic Heart Valve Low INR Post-Market Study Presented in A Late-Breaking Science Session At the 37European Association for Cardio-Thoracic Surgery Annual Meeting

Artivion, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Senior Vice President of Operations recently sold US$248k worth of stock

Price target increased by 10% to US$24.90

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Artivion Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Chairman recently sold US$293k worth of stock

Artivion, Inc. Provides Earnings Outlook for the Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Insider exercised options to buy US$115k worth of stock.

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Artivion, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold

Price target decreased to US$23.13

Price target decreased to US$23.13

Artivion, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.27 profit in 3Q 2021)